HomeHealthcare & Life Sciences PCSK9-Targeted Therapy Market

Global PCSK9-Targeted Therapy Market Size, Share & Trends Analysis Report By Drug Type / Modality (Monoclonal Antibodies (mAbs)Â AlirocumabÂ EvolocumabÂ , siRNA-based TherapiesÂ InclisiranÂ , Gene Editing and Other Novel ModalitiesÂ CRISPR-based approachesÂ Antisense oligonucleotides (ASOs)Â ), By IndicationÂ (Heterozygous Familial Hypercholesterolemia (HeFH)Â , Atherosclerotic Cardiovascular Disease (ASCVD)Â , Homozygous Familial Hypercholesterolemia (HoFH)Â , Hyperlipidemia (Non-FH)Â ), By Co

Starting From
USD 3950

Buy Now

Report Benefits

Develop business strategies by understanding the trends shaping and driving the Market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track sales in the global and country-specific Market.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Market Segmentation

PCSK9-Targeted Therapy Market, By Drug Type / Modality (Million 2022-2034)
- Monoclonal Antibodies (mAbs)
  - Alirocumab
  - Evolocumab
- siRNA-based Therapies
  - Inclisiran
- Gene Editing and Other Novel Modalities
  - CRISPR-based approaches
  - Antisense oligonucleotides (ASOs)
PCSK9-Targeted Therapy Market, By Indication (Million 2022-2034)
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Homozygous Familial Hypercholesterolemia (HoFH)
- Hyperlipidemia (Non-FH)
PCSK9-Targeted Therapy Market, By Route of Administration (Million 2022-2034)
- Subcutaneous Injection
- Intravenous Injection
- Oral (in pipeline)
PCSK9-Targeted Therapy Market, By Distribution Channel (Million 2022-2034)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
PCSK9-Targeted Therapy Market, By Patient Type (Million 2022-2034)
- Primary Prevention (High Risk, No History of ASCVD)
- Secondary Prevention (With History of ASCVD)
- Statin-Intolerant Patients
Regional PCSK9-Targeted Therapy Market, By Patient Type (Million 2022-2034)
- North America
  - North America PCSK9-Targeted Therapy Market, By Drug Type / Modality
    - Monoclonal Antibodies (mAbs)
    - siRNA-based Therapies
    - Gene Editing and Other Novel Modalities
  - North America PCSK9-Targeted Therapy Market, By Indication
    - Heterozygous Familial Hypercholesterolemia (HeFH)
    - Atherosclerotic Cardiovascular Disease (ASCVD)
    - Homozygous Familial Hypercholesterolemia (HoFH)
    - Hyperlipidemia (Non-FH)
  - North America PCSK9-Targeted Therapy Market, By Route of Administration
    - Subcutaneous Injection
    - Intravenous Injection
    - Oral (in pipeline)
  - North America PCSK9-Targeted Therapy Market, By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - North America PCSK9-Targeted Therapy Market, By Patient Type
    - Primary Prevention (High Risk, No History of ASCVD)
    - Secondary Prevention (With History of ASCVD)
    - Statin-Intolerant Patients
  - U.S.
    - U.S. PCSK9-Targeted Therapy Market, By Drug Type / Modality
      - Monoclonal Antibodies (mAbs)
      - siRNA-based Therapies
      - Gene Editing and Other Novel Modalities
    - U.S. PCSK9-Targeted Therapy Market, By Indication
      - Heterozygous Familial Hypercholesterolemia (HeFH)
      - Atherosclerotic Cardiovascular Disease (ASCVD)
      - Homozygous Familial Hypercholesterolemia (HoFH)
      - Hyperlipidemia (Non-FH)
    - U.S. PCSK9-Targeted Therapy Market, By Route of Administration
      - Subcutaneous Injection
      - Intravenous Injection
      - Oral (in pipeline)
    - U.S. PCSK9-Targeted Therapy Market, By Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
    - U.S. PCSK9-Targeted Therapy Market, By Patient Type
      - Primary Prevention (High Risk, No History of ASCVD)
      - Secondary Prevention (With History of ASCVD)
      - Statin-Intolerant Patients
  - Canada
- Europe
  - Europe PCSK9-Targeted Therapy Market, By Drug Type / Modality
    - Monoclonal Antibodies (mAbs)
    - siRNA-based Therapies
    - Gene Editing and Other Novel Modalities
  - Europe PCSK9-Targeted Therapy Market, By Indication
    - Heterozygous Familial Hypercholesterolemia (HeFH)
    - Atherosclerotic Cardiovascular Disease (ASCVD)
    - Homozygous Familial Hypercholesterolemia (HoFH)
    - Hyperlipidemia (Non-FH)
  - Europe PCSK9-Targeted Therapy Market, By Route of Administration
    - Subcutaneous Injection
    - Intravenous Injection
    - Oral (in pipeline)
  - Europe PCSK9-Targeted Therapy Market, By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - Europe PCSK9-Targeted Therapy Market, By Patient Type
    - Primary Prevention (High Risk, No History of ASCVD)
    - Secondary Prevention (With History of ASCVD)
    - Statin-Intolerant Patients
  - U.K.
    - U.K. PCSK9-Targeted Therapy Market, By Drug Type / Modality
      - Monoclonal Antibodies (mAbs)
      - siRNA-based Therapies
      - Gene Editing and Other Novel Modalities
    - U.K. PCSK9-Targeted Therapy Market, By Indication
      - Heterozygous Familial Hypercholesterolemia (HeFH)
      - Atherosclerotic Cardiovascular Disease (ASCVD)
      - Homozygous Familial Hypercholesterolemia (HoFH)
      - Hyperlipidemia (Non-FH)
    - U.K. PCSK9-Targeted Therapy Market, By Route of Administration
      - Subcutaneous Injection
      - Intravenous Injection
      - Oral (in pipeline)
    - U.K. PCSK9-Targeted Therapy Market, By Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
    - U.K. PCSK9-Targeted Therapy Market, By Patient Type
      - Primary Prevention (High Risk, No History of ASCVD)
      - Secondary Prevention (With History of ASCVD)
      - Statin-Intolerant Patients
  - Germany
  - France
  - Spain
  - Italy
  - Russia
  - Nordic
  - Benelux
  - Rest of Europe
- APAC
  - APAC PCSK9-Targeted Therapy Market, By Drug Type / Modality
    - Monoclonal Antibodies (mAbs)
    - siRNA-based Therapies
    - Gene Editing and Other Novel Modalities
  - APAC PCSK9-Targeted Therapy Market, By Indication
    - Heterozygous Familial Hypercholesterolemia (HeFH)
    - Atherosclerotic Cardiovascular Disease (ASCVD)
    - Homozygous Familial Hypercholesterolemia (HoFH)
    - Hyperlipidemia (Non-FH)
  - APAC PCSK9-Targeted Therapy Market, By Route of Administration
    - Subcutaneous Injection
    - Intravenous Injection
    - Oral (in pipeline)
  - APAC PCSK9-Targeted Therapy Market, By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - APAC PCSK9-Targeted Therapy Market, By Patient Type
    - Primary Prevention (High Risk, No History of ASCVD)
    - Secondary Prevention (With History of ASCVD)
    - Statin-Intolerant Patients
  - China
    - China PCSK9-Targeted Therapy Market, By Drug Type / Modality
      - Monoclonal Antibodies (mAbs)
      - siRNA-based Therapies
      - Gene Editing and Other Novel Modalities
    - China PCSK9-Targeted Therapy Market, By Indication
      - Heterozygous Familial Hypercholesterolemia (HeFH)
      - Atherosclerotic Cardiovascular Disease (ASCVD)
      - Homozygous Familial Hypercholesterolemia (HoFH)
      - Hyperlipidemia (Non-FH)
    - China PCSK9-Targeted Therapy Market, By Route of Administration
      - Subcutaneous Injection
      - Intravenous Injection
      - Oral (in pipeline)
    - China PCSK9-Targeted Therapy Market, By Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
    - China PCSK9-Targeted Therapy Market, By Patient Type
      - Primary Prevention (High Risk, No History of ASCVD)
      - Secondary Prevention (With History of ASCVD)
      - Statin-Intolerant Patients
  - South Korea
  - Japan
  - India
  - Australia
  - Singapore
  - Taiwan
  - South East Asia
  - Rest of Asia-Pacific
- Middle East and Africa
  - Middle East and Africa PCSK9-Targeted Therapy Market, By Drug Type / Modality
    - Monoclonal Antibodies (mAbs)
    - siRNA-based Therapies
    - Gene Editing and Other Novel Modalities
  - Middle East and Africa PCSK9-Targeted Therapy Market, By Indication
    - Heterozygous Familial Hypercholesterolemia (HeFH)
    - Atherosclerotic Cardiovascular Disease (ASCVD)
    - Homozygous Familial Hypercholesterolemia (HoFH)
    - Hyperlipidemia (Non-FH)
  - Middle East and Africa PCSK9-Targeted Therapy Market, By Route of Administration
    - Subcutaneous Injection
    - Intravenous Injection
    - Oral (in pipeline)
  - Middle East and Africa PCSK9-Targeted Therapy Market, By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - Middle East and Africa PCSK9-Targeted Therapy Market, By Patient Type
    - Primary Prevention (High Risk, No History of ASCVD)
    - Secondary Prevention (With History of ASCVD)
    - Statin-Intolerant Patients
  - UAE
    - UAE PCSK9-Targeted Therapy Market, By Drug Type / Modality
      - Monoclonal Antibodies (mAbs)
      - siRNA-based Therapies
      - Gene Editing and Other Novel Modalities
    - UAE PCSK9-Targeted Therapy Market, By Indication
      - Heterozygous Familial Hypercholesterolemia (HeFH)
      - Atherosclerotic Cardiovascular Disease (ASCVD)
      - Homozygous Familial Hypercholesterolemia (HoFH)
      - Hyperlipidemia (Non-FH)
    - UAE PCSK9-Targeted Therapy Market, By Route of Administration
      - Subcutaneous Injection
      - Intravenous Injection
      - Oral (in pipeline)
    - UAE PCSK9-Targeted Therapy Market, By Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
    - UAE PCSK9-Targeted Therapy Market, By Patient Type
      - Primary Prevention (High Risk, No History of ASCVD)
      - Secondary Prevention (With History of ASCVD)
      - Statin-Intolerant Patients
  - Turky
  - Saudi Arabia
  - South Africa
  - Egypt
  - Nigeria
  - Rest of MEA
- LATAM
  - LATAM PCSK9-Targeted Therapy Market, By Drug Type / Modality
    - Monoclonal Antibodies (mAbs)
    - siRNA-based Therapies
    - Gene Editing and Other Novel Modalities
  - LATAM PCSK9-Targeted Therapy Market, By Indication
    - Heterozygous Familial Hypercholesterolemia (HeFH)
    - Atherosclerotic Cardiovascular Disease (ASCVD)
    - Homozygous Familial Hypercholesterolemia (HoFH)
    - Hyperlipidemia (Non-FH)
  - LATAM PCSK9-Targeted Therapy Market, By Route of Administration
    - Subcutaneous Injection
    - Intravenous Injection
    - Oral (in pipeline)
  - LATAM PCSK9-Targeted Therapy Market, By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - LATAM PCSK9-Targeted Therapy Market, By Patient Type
    - Primary Prevention (High Risk, No History of ASCVD)
    - Secondary Prevention (With History of ASCVD)
    - Statin-Intolerant Patients
  - Brazil
    - Brazil PCSK9-Targeted Therapy Market, By Drug Type / Modality
      - Monoclonal Antibodies (mAbs)
      - siRNA-based Therapies
      - Gene Editing and Other Novel Modalities
    - Brazil PCSK9-Targeted Therapy Market, By Indication
      - Heterozygous Familial Hypercholesterolemia (HeFH)
      - Atherosclerotic Cardiovascular Disease (ASCVD)
      - Homozygous Familial Hypercholesterolemia (HoFH)
      - Hyperlipidemia (Non-FH)
    - Brazil PCSK9-Targeted Therapy Market, By Route of Administration
      - Subcutaneous Injection
      - Intravenous Injection
      - Oral (in pipeline)
    - Brazil PCSK9-Targeted Therapy Market, By Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
    - Brazil PCSK9-Targeted Therapy Market, By Patient Type
      - Primary Prevention (High Risk, No History of ASCVD)
      - Secondary Prevention (With History of ASCVD)
      - Statin-Intolerant Patients
  - Mexico
  - Argentina
  - Chile
  - Colombia
  - Rest of LATAM